Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mifamurtide + MF59
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Mifamurtide (L-MTP-PE) is a synthetic analog of muramyl dipeptide conjugated to phosphatidylethanolamine and encapsulated in liposomes. It acts as an immunomodulator by activating macrophages to destroy tumor cells and has been developed primarily for the treatment of osteosarcoma. When combined with the oil-in-water emulsion adjuvant MF59, this formulation is used as a vaccine adjuvant to enhance both humoral and cellular immune responses. The combination has been studied in cancer immunotherapy (notably osteosarcoma) and as an adjuvant in experimental vaccines for infectious diseases such as HIV and hepatitis B virus. The addition of MTP-PE to MF59 increases local and systemic immune reactions compared to either component alone[1][2][3][7].
- Brand names
- JunovanL-MTP-PE
- Other names
- muramyl tripeptide phosphatidylethanolamine + MF59MTP-PE + MF59
02
Targets
NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on Mifamurtide + MF59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mifamurtide + MF59.